StreetInsider.com News Articles

Dyadic launches enzyme program targeting cellulose processing

Thu, 16 Jul 2026 08:03:47 -0400

Dyadic International, Inc. (NASDAQ: DYAI), operating as Dyadic Applied BioSolutions, announced the expansion of its bio-industrial pipeline with a new proprietary industrial enzyme program focused on advanced cellulose processing.

The program follows the commercialization of EN3ZYME™, Dyadic's first proprietary bio-industrial enzyme product developed in collaboration with Fermbox Bio. The new enzyme is designed for applications including pulp biorefining, microcrystalline cellulose production, and nanocellulose production.

Dyadic said the program utilizes its Dapibus™ microbial expression platform, which uses a single microbial production strain. The company stated this approach is intended to streamline development timelines and reduce manufacturing complexity compared to traditional multi-strain systems.

The program

Dyadic Expands Bio industrial Pipeline with New Proprietary Industrial Enzyme Program

Thu, 16 Jul 2026 08:00:00 -0400

New initiative builds on EN3ZYME™ launch and highlights scalability of the Dapibus™ platform

JUPITER, Fla., July 16, 2026 (GLOBE NEWSWIRE) -- Dyadic International, Inc. (Nasdaq: DYAI) ("Dyadic" or the "Company"), d/b/a Dyadic Applied BioSolutions, a biotechnology company developing recombinant protein solutions across the life sciences, food, nutrition, bio-industrial and biopharmaceutical markets, today announced the expansion of its bio-industrial pipeline with a new proprietary industrial enzyme program focused on advanced cellulose processing.

The program builds on the successful commercialization of EN3ZYME™, Dyadic's first proprietary bio-industrial enzyme product developed in collaboration with Fermbox Bio and further demonstrates the

Dyadic Expands Bio industrial Pipeline with New Proprietary Industrial Enzyme Program

Thu, 16 Jul 2026 08:00:00 -0400

New initiative builds on EN3ZYME™ launch and highlights scalability of the Dapibus™ platform

The program builds on the successful commercialization of EN3ZYME™, Dyadic's first proprietary bio-industrial enzyme product developed in collaboration with Fermbox Bio and further demonstrates the

Dyadic receives full $3.1M Gates grant, advances C1 platform work

Tue, 07 Jul 2026 07:25:32 -0400

Dyadic International, Inc. (Nasdaq: DYAI), operating as Dyadic Applied BioSolutions, has received the full $3.1 million Gates Foundation grant, including a final payment of $738,743 in June 2026, to fund research on its C1 protein production platform for monoclonal antibody applications targeting RSV and malaria.

According to a company statement, studies have shown that monoclonal antibodies produced using the C1 platform demonstrated binding and neutralization characteristics comparable to those produced with traditional CHO cell systems, while achieving higher production yields at lower projected manufacturing costs. The company also reported that multiple production runs were completed within the time typically required for

Global Collaborations Continue to Validate Dyadic’s C1 Platform and Expands Commercial Potential

Tue, 07 Jul 2026 07:25:00 -0400

C1 Monoclonal Antibody Progress for RSV and Malaria Following Full $3.1 Million Gates Foundation Grant Funding

JUPITER, Fla., July 07, 2026 (GLOBE NEWSWIRE) -- Dyadic International, Inc. (Nasdaq: DYAI) (“Dyadic” or the “Company”), d/b/a Dyadic Applied BioSolutions, a biotechnology company focused on the development and commercialization of scalable microbial protein production platforms for use across life sciences, food, nutrition, industrial, and biopharmaceutical sectors, today highlighted continued progress across multiple global health collaborations that further validate the capabilities of its proprietary C1 protein production platform while supporting its broader commercialization strategy.

Dyadic’s C1 platform is designed to

Global Collaborations Continue to Validate Dyadic’s C1 Platform and Expands Commercial Potential

Tue, 07 Jul 2026 07:25:00 -0400

C1 Monoclonal Antibody Progress for RSV and Malaria Following Full $3.1 Million Gates Foundation Grant Funding

Dyadic’s C1 platform is designed to

Form 4 DYADIC INTERNATIONAL For: Mar 08 Filed by: Francisco Trust under agreement dated February 28, 1996

Mon, 06 Jul 2026 06:30:00 -0400

si-local-file:///var/storage/secattach/20260706/26732419.html

Form 4 DYADIC INTERNATIONAL For: Mar 08 Filed by: Francisco Trust under agreement dated February 28, 1996

Mon, 06 Jul 2026 06:30:00 -0400

si-local-file:///var/storage/secattach/20260706/26732419.html

Form SCHEDULE 13G/A DYADIC INTERNATIONAL Filed by: Francisco Trust under agreement dated February 28, 1996

Mon, 06 Jul 2026 06:30:00 -0400

si-local-file:///var/storage/secattach/20260706/26732420.html

Form SCHEDULE 13G/A DYADIC INTERNATIONAL Filed by: Francisco Trust under agreement dated February 28, 1996

Mon, 06 Jul 2026 06:30:00 -0400

si-local-file:///var/storage/secattach/20260706/26732420.html

Dyadic wins Japan patent for protein expression technology

Mon, 29 Jun 2026 07:28:25 -0400

Dyadic International, Inc. (NASDAQ: DYAI) announced that the Japan Patent Office has allowed claims covering its proprietary Thermothelomyces heterothallica recombinant protein expression technology, according to a press release issued June 29, 2026.

The allowed claims cover novel aspects of Dyadic's C1 and Dapibus™ microbial production platforms, adding to the company's global intellectual property portfolio.

"This patent represents an important milestone in our strategy to expand Dyadic's intellectual property position and commercial opportunities in one of the world's most advanced biotechnology markets," said Joe Hazelton, Dyadic's President and Chief Operating Officer.

Dyadic also announced it has engaged Intralink, an international business development firm, to

Dyadic Expands IP Protection and Business Development Activities in Japan

Mon, 29 Jun 2026 07:25:00 -0400

Bolsters Japan Market Expansion, Strategic Collaborations and Demand for Scalable Recombinant Protein Solutions

JUPITER, Fla., June 29, 2026 (GLOBE NEWSWIRE) -- Dyadic International, Inc. (Nasdaq: DYAI) (“Dyadic” or the “Company”), d/b/a Dyadic Applied BioSolutions, a biotechnology company focused on the development and commercialization of scalable microbial protein production platforms for use across life sciences, food, nutrition, industrial, and biopharmaceutical sectors, today announced that the Japan Patent Office has allowed claims covering its proprietary Thermothelomyces heterothallica recombinant protein expression technology.

The Japan Patent Office allowed claims covering novel aspects of Dyadic’s proprietary Thermothelomyces heterothallica recombinant protein expression technology. This milestone

Dyadic Expands IP Protection and Business Development Activities in Japan

Mon, 29 Jun 2026 07:25:00 -0400

Bolsters Japan Market Expansion, Strategic Collaborations and Demand for Scalable Recombinant Protein Solutions

The Japan Patent Office allowed claims covering novel aspects of Dyadic’s proprietary Thermothelomyces heterothallica recombinant protein expression technology. This milestone

An Interview with the President & COO: How Dyadic is Commercializing Its Protein Platform Across Multi-Billion-Dollar Markets

Mon, 22 Jun 2026 08:46:00 -0400

SmallCaps Daily Sits Down with Joe Hazelton to Discuss Dyadic's Product Strategy, Strategic Partnerships, and Long-Term Growth Vision

New York, New York--(Newsfile Corp. - June 22, 2026) - Dyadic Applied BioSolutions, Inc. (NASDAQ: DYAI) ("Dyadic" or the "Company") is entering the next phase of its growth strategy as it expands commercialization efforts across Life Sciences, Food & Nutrition, and Bio-industrial markets. SmallCaps Daily sat down with President and Chief Operating Officer Joe Hazelton to discuss the Company's product portfolio, strategic partnerships, and growing opportunities in non-animal proteins.

With commercial products now launched through partners, including ProLiant Health and Biologics, and additional products

An Interview with the President & COO: How Dyadic is Commercializing Its Protein Platform Across Multi-Billion-Dollar Markets

Mon, 22 Jun 2026 08:46:00 -0400

SmallCaps Daily Sits Down with Joe Hazelton to Discuss Dyadic's Product Strategy, Strategic Partnerships, and Long-Term Growth Vision

With commercial products now launched through partners, including ProLiant Health and Biologics, and additional products

Form 8-K DYADIC INTERNATIONAL For: Jun 18

Mon, 22 Jun 2026 08:30:00 -0400

si-local-file:///var/storage/secattach/20260622/26670426.html

Form 8-K DYADIC INTERNATIONAL For: Jun 18

Mon, 22 Jun 2026 08:30:00 -0400

si-local-file:///var/storage/secattach/20260622/26670426.html

Form 8-K DYADIC INTERNATIONAL For: Jun 18

Thu, 18 Jun 2026 09:56:00 -0400

si-local-file:///var/storage/secattach/20260618/26664027.html

Form 8-K DYADIC INTERNATIONAL For: Jun 18

Thu, 18 Jun 2026 09:56:00 -0400

si-local-file:///var/storage/secattach/20260618/26664027.html

Form DEFA14A DYADIC INTERNATIONAL

Thu, 18 Jun 2026 09:56:00 -0400

si-local-file:///var/storage/secattach/20260618/26664028.html

Form DEFA14A DYADIC INTERNATIONAL

Thu, 18 Jun 2026 09:56:00 -0400

si-local-file:///var/storage/secattach/20260618/26664028.html

Form 8-K DYADIC INTERNATIONAL For: Jun 15

Mon, 15 Jun 2026 16:30:00 -0400

si-local-file:///var/storage/secattach/20260615/26647853.html

Form 8-K DYADIC INTERNATIONAL For: Jun 15

Mon, 15 Jun 2026 16:30:00 -0400

si-local-file:///var/storage/secattach/20260615/26647853.html

Dyadic sees increased interest in C1 platform amid Ebola outbreak response

Mon, 15 Jun 2026 07:27:31 -0400

Dyadic International Inc. (NASDAQ: DYAI) reported growing interest in its C1 protein production platform as global health organizations respond to the ongoing Bundibugyo Ebola virus outbreak and the company advances commercial adoption across multiple markets.

The biotechnology company said its C1 platform can progress from receipt of a codon-optimized viral gene sequence to purified recombinant antigen or monoclonal antibody in approximately 15 days. The platform uses microbial manufacturing processes that the company says may support rapid vaccine and antibody production during infectious disease outbreaks.

Dyadic has initiated three tracks related to Ebola preparedness. The company announced a collaboration with Scripps Research to

Dyadic Highlights Accelerated Interest in C1 Biomanufacturing Platform Amid Ebola Preparedness Activities and Growing Commercial Adoption

Mon, 15 Jun 2026 07:25:00 -0400

Company’s C1 platform may help address urgent need for rapid, scalable vaccine and antibody manufacturing while supporting broader commercialization across life sciences, food, nutrition and industrial markets

JUPITER, Fla., June 15, 2026 (GLOBE NEWSWIRE) -- Dyadic International, Inc. (Nasdaq: DYAI), d/b/a Dyadic Applied BioSolutions (“Dyadic” or the “Company”), a biotechnology company focused on the development and commercialization of scalable microbial protein production platforms, today highlighted increasing interest in its proprietary C1 protein production platform as global infectious disease preparedness efforts intensify in response to the ongoing Bundibugyo Ebola virus (BDBV) outbreak and as the Company continues to advance commercial